HighPoint Advisor Group LLC grew its holdings in shares of GlaxoSmithKline PLC (NYSE:GSK) by 10.0% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 16,735 shares of the pharmaceutical company’s stock after buying an additional 1,522 shares during the period. HighPoint Advisor Group LLC’s holdings in GlaxoSmithKline PLC were worth $602,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds and other institutional investors have also made changes to their positions in GSK. Renaissance Technologies LLC lifted its holdings in GlaxoSmithKline PLC by 112.1% during the 2nd quarter. Renaissance Technologies LLC now owns 9,338,000 shares of the pharmaceutical company’s stock worth $402,655,000 after buying an additional 4,935,900 shares during the last quarter. FMR LLC lifted its holdings in GlaxoSmithKline PLC by 5.9% during the 2nd quarter. FMR LLC now owns 25,024,276 shares of the pharmaceutical company’s stock worth $1,079,047,000 after buying an additional 1,389,238 shares during the last quarter. Federated Investors Inc. PA lifted its holdings in GlaxoSmithKline PLC by 22.7% during the 2nd quarter. Federated Investors Inc. PA now owns 4,511,155 shares of the pharmaceutical company’s stock worth $194,521,000 after buying an additional 833,501 shares during the last quarter. Marshall Wace North America L.P. lifted its holdings in shares of GlaxoSmithKline PLC by 148.0% in the 2nd quarter. Marshall Wace North America L.P. now owns 1,119,491 shares of the pharmaceutical company’s stock valued at $48,138,000 after purchasing an additional 668,088 shares during the last quarter. Finally, Fisher Asset Management LLC lifted its holdings in shares of GlaxoSmithKline PLC by 4.7% in the 2nd quarter. Fisher Asset Management LLC now owns 12,534,385 shares of the pharmaceutical company’s stock valued at $540,483,000 after purchasing an additional 564,519 shares during the last quarter. 9.32% of the stock is owned by institutional investors.
In related news, major shareholder Plc Glaxosmithkline purchased 428,571 shares of the company’s stock in a transaction that occurred on Monday, November 6th. The shares were purchased at an average price of $14.00 per share, for a total transaction of $5,999,994.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 10.00% of the company’s stock.
Shares of GlaxoSmithKline PLC (NYSE GSK) traded down $0.14 during mid-day trading on Tuesday, reaching $34.95. The company had a trading volume of 2,492,276 shares, compared to its average volume of 3,432,454. The firm has a market cap of $86,814.73, a PE ratio of 12.52, a PEG ratio of 1.96 and a beta of 1.00. GlaxoSmithKline PLC has a 1 year low of $34.97 and a 1 year high of $44.53. The company has a debt-to-equity ratio of 2.96, a current ratio of 0.64 and a quick ratio of 0.44.
The business also recently declared a quarterly dividend, which will be paid on Thursday, January 11th. Investors of record on Friday, November 10th will be given a $0.5037 dividend. This represents a $2.01 annualized dividend and a yield of 5.76%. The ex-dividend date of this dividend is Thursday, November 9th. This is a boost from GlaxoSmithKline PLC’s previous quarterly dividend of $0.49. GlaxoSmithKline PLC’s payout ratio is 163.12%.
Several analysts have recently weighed in on GSK shares. Zacks Investment Research downgraded GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a report on Tuesday, October 24th. Morgan Stanley downgraded GlaxoSmithKline PLC from an “equal weight” rating to an “underweight” rating in a report on Friday, September 8th. BidaskClub raised GlaxoSmithKline PLC from a “strong sell” rating to a “sell” rating in a report on Friday, August 25th. Argus reissued a “buy” rating and issued a $50.00 target price on shares of GlaxoSmithKline PLC in a report on Thursday, August 31st. Finally, TheStreet raised GlaxoSmithKline PLC from a “c+” rating to a “b” rating in a report on Wednesday, October 25th. Three equities research analysts have rated the stock with a sell rating, ten have given a hold rating and five have assigned a buy rating to the stock. GlaxoSmithKline PLC has an average rating of “Hold” and an average target price of $44.33.
GlaxoSmithKline PLC Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline PLC (NYSE:GSK).
Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.